Brief: Iterum Therapeutics Announces FDA Advisory Committee Meeting To Discuss NDA For Oral Sulopenem For Treating Uncomplicated Urinary Tract Infections
21/06/2024 13:38
June 21 (Reuters) - Iterum Therapeutics PLC ITRM.O :
* ITERUM THERAPEUTICS ANNOUNCES FDA ADVISORY COMMITTEE
MEETING TO
DISCUSS NDA FOR ORAL SULOPENEM FOR THE TREATMENT OF
UNCOMPLICATED URINARY TRACT INFECTIONS
* ITERUM THERAPEUTICS PLC - FDA HAS ASSIGNED A PDUFA ACTION
DATE
OF OCTOBER 25, 2024.
* ITERUM THERAPEUTICS PLC - PROPOSED DATE FOR FDA ADVISORY
COMMITTEE MEETING IS SEPTEMBER 9, 2024.
Source text for Eikon: ID:nGNX8wThLx
Further company coverage: ITRM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Iterum Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Iterum Therapeutics plummets after filing wind up petition
Iterum seeks court-led dissolution amid cash crisis, inability to raise funds (updated)
Iterum files wind-up petition due to limited cash, inability to raise equity